The Assessment and Treatment of Antipsychotic-Induced Akathisia

被引:37
|
作者
Pringsheim, Tamara [1 ]
Gardner, David [2 ]
Addington, Donald [3 ]
Martino, Davide [4 ]
Morgante, Francesca [5 ,6 ]
Ricciardi, Lucia [7 ]
Poole, Norman [8 ]
Remington, Gary [9 ,10 ]
Edwards, Mark [11 ]
Carson, Alan [12 ]
Barnes, Thomas R. E. [13 ]
机构
[1] Univ Calgary, Dept Clin Neurosci Psychiat Pediat & Community Hl, Calgary, AB, Canada
[2] Dalhousie Univ, Dept Psychiat & Pharm, Halifax, NS, Canada
[3] Univ Calgary, Dept Psychiat, Calgary, AB, Canada
[4] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[5] Univ Messina, Dept Clin & Expt Med, Messina, Italy
[6] St Georges Univ London, Inst Mol & Clin Sci, London, England
[7] St Georges Univ London, Inst Cardiovasc & Cell Sci, London, England
[8] Kings Coll London, Dept Philosophy, London, England
[9] Univ Toronto, CAMH, Schizophrenia Div, Dept Psychiat, Toronto, ON, Canada
[10] Univ Toronto, CAMH, Schizophrenia Div, Dept Psychol Clin Sci, Toronto, ON, Canada
[11] St Georges Univ London, Dept Neurol, London, England
[12] Univ Edinburgh, Div Psychiat, Edinburgh, Midlothian, Scotland
[13] Imperial Coll London, Dept Psychiat, London, England
关键词
antipsychotics; extrapyramidal syndromes; evidence-based medicine; NEUROLEPTIC-INDUCED AKATHISIA; INDUCED MOVEMENT-DISORDERS; LOW-DOSE MIRTAZAPINE; DOUBLE-BLIND; TARDIVE-DYSKINESIA; RATING-SCALE; WITHDRAWAL AKATHISIA; BARNES AKATHISIA; CONTROLLED TRIAL; PLACEBO;
D O I
10.1177/0706743718760288
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Akathisia is a common and distressing neuropsychiatric syndrome associated with antipsychotic medication, characterised by subjective and objective psychomotor restlessness. The goal of this guideline is to provide clinicians with recommendations on the assessment and treatment of akathisia. Methods: We performed a systematic review of therapeutic studies assessing the treatment of antipsychotic-induced extrapyramidal symptoms. Forty studies on akathisia and 4 systematic reviews evaluating the adverse effects of antipsychotics were used in the formulation of recommendations. Studies were rated for methodological quality using the American Academy of Neurology Risk of Bias Classification system. The overall level of evidence classifications and grades of recommendation were made using the Scottish Intercollegiate Guidelines Network framework. Results: As a good practice point, clinicians should systematically assess akathisia with a validated scale before starting antipsychotics and during antipsychotic dosage titration. For the management of akathisia, there was adequate evidence to allow recommendations regarding antipsychotic dose reduction, antipsychotic polypharmacy, switching antipsychotic medication, and the use of adjuvant medications including beta-blockers, anticholinergics, 5HT(2A) antagonists, benzodiazepines, and vitamin B6. Conclusion: The treatment of antipsychotic-induced akathisia should be personalised, with consideration of antipsychotic dose reduction, cessation of antipsychotic polypharmacy, and switching to an antipsychotic with a perceived lower liability for akathisia, before the use of adjuvant medications. The choice of adjuvant medications should favour the more established treatments, with careful consideration of contraindications and side effects. Limitations in the evidence should be acknowledged and prompt cautious prescribing, particularly with respect to the duration of use of adjuvant medications, is warranted.
引用
收藏
页码:719 / 729
页数:11
相关论文
共 50 条
  • [31] Topiramate in the treatment of antipsychotic-induced hyperprolactinemia
    Huang, Ying-lin
    Peng, Miao
    Zhu, Gang
    MEDICAL HYPOTHESES, 2020, 138
  • [32] Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-analysis
    Furukawa, Yuki
    Imai, Kota
    Takahashi, Yusuke
    Efthimiou, Orestis
    Leucht, Stefan
    SCHIZOPHRENIA BULLETIN, 2024,
  • [33] Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report
    Sullivan, Maria A.
    Wilbur, Robert
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2014, 4 (02) : 100 - 102
  • [34] Assessment and management of antipsychotic-induced adverse events
    Cortese, L
    Pourcher-Bouchard, E
    Williams, R
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1998, 43 : 15S - 20S
  • [35] Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia
    Erbe, Sebastian
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2019, 87 (04) : 217 - 224
  • [36] Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension
    Tse, Lurdes
    Procyshyn, Ric M.
    Fredrikson, Diane H.
    Boyda, Heidi N.
    Honer, William G.
    Barr, Alasdair M.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (03) : 125 - 137
  • [37] Connection between the constitutional-morphological markers and the risk of antipsychotic-induced akathisia in patients with schizophrenia
    Goncharova, A.
    Kornetova, E.
    Dmitrieva, E.
    Kornetov, A.
    EUROPEAN PSYCHIATRY, 2020, 63 : S241 - S241
  • [38] Antipsychotic-induced hyperprolactinemia
    Khouadja, S.
    Ben Soussia, R.
    Bouallagui, A.
    Marrag, I.
    Younes, S.
    Nasr, M.
    EUROPEAN PSYCHIATRY, 2017, 41 : S701 - S701
  • [39] Antipsychotic-Induced Hyperprolactinemia
    Bostwick, Jolene R.
    Guthrie, Sally K.
    Ellingrod, Vicki L.
    PHARMACOTHERAPY, 2009, 29 (01): : 64 - 73
  • [40] ANTIPSYCHOTIC-INDUCED HYPERPROLACTINAEMIA
    Mendes, J. C.
    Oliveira, S.
    Ferreira, S.
    EUROPEAN PSYCHIATRY, 2012, 27